Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | TYK2 | P29597 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648913 | 1.00 | JAK2 (0.39) | JAK2JAK3TYK2JAK1HTR2A | |
| SCHEMBL23168749 | 1.00 | JAK2 (0.39) | JAK2JAK3TYK2JAK1HTR2A | |
| SCHEMBL29467008 | 1.00 | JAK2 (0.39) | JAK2JAK3TYK2JAK1HTR2A | |
| SCHEMBL22638029 | 0.84 | JAK2 (0.48) | JAK2JAK3TYK2JAK1HTR2A | |
| SCHEMBL22648842 | 0.80 | JAK2 (0.45) | JAK2JAK3TYK2JAK1RPS6KA3 | |
| SCHEMBL29467010 | 0.80 | JAK2 (0.45) | JAK2JAK3TYK2JAK1RPS6KA3 | |
| SCHEMBL22638003 | 0.80 | JAK2 (0.45) | JAK2JAK3TYK2JAK1RPS6KA3 | |
| SCHEMBL30881456 | 0.79 | JAK2 (0.33) | JAK2JAK3TYK2JAK1RPS6KA3 | |
| SCHEMBL17066933 | 0.79 | JAK2 (0.33) | JAK2JAK3TYK2JAK1RPS6KA3 | |
| SCHEMBL22638005 | 0.76 | JAK2 (0.41) | JAK2JAK3TYK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024521-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-115003300-A | JAK inhibitors | 维玛兰生物科学公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210040100-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200369669-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369669-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885TYK2 8/4885 |
| US-11136329-B2 | JAK inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885TYK2 6/4885 |
| US-20230024521-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885TYK2 8/4885 |
| US-20210040100-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885TYK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.